229 related articles for article (PubMed ID: 15522280)
1. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
3. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
4. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
5. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.
Carlsson L; Andersson B; Linhardt G; Löfberg L
J Cardiovasc Pharmacol; 2009 Jul; 54(1):82-9. PubMed ID: 19528812
[TBL] [Abstract][Full Text] [Related]
7. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
8. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
Jaiswal A; Goldbarg S
Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
[TBL] [Abstract][Full Text] [Related]
9. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
10. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
[TBL] [Abstract][Full Text] [Related]
13. Dofetilide-induced long QT and torsades de pointes.
Aktas MK; Shah AH; Akiyama T
Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
[TBL] [Abstract][Full Text] [Related]
14. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits.
Huang ZJ; Dai DZ; Li N; Na T; Ji M; Dai Y
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):310-7. PubMed ID: 17324143
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
16. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
Dhein S; Perlitz F; Mohr FW
Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):631-44. PubMed ID: 18648775
[TBL] [Abstract][Full Text] [Related]
17. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
18. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
19. Drug block of I(kr): model systems and relevance to human arrhythmias.
Yang T; Snyders D; Roden DM
J Cardiovasc Pharmacol; 2001 Nov; 38(5):737-44. PubMed ID: 11602820
[TBL] [Abstract][Full Text] [Related]
20. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
